IFRXInflaRx N.V.
IFRX
InflaRx N.V.10,471
Mkt Cap
$188.68MVolume
1.51M52W High
$2.9552W Low
$0.7113PE Ratio
-2.49IFRX Fundamentals
Price
$2.61Prev Close
$2.47Open
$2.5250D MA
$1.58Beta
1.16Avg. Volume
1.5MEPS (Annual)
-$0.7654P/B
4.44Rev/Employee
$509.26$14.45
Biotech Surges as Big Money Backs High-Stakes Kidney Disease Push
The immune system has become one of biotech's most important battlegrounds as drug developers race to target inflammatory pathways responsible for some of medicine's most difficult-to-treat diseases. Among the most closely watched areas is the complement system, a network of proteins that can trigger severe tissue damage when overactivated. With growing interest in kidney disorders and autoimmune diseases, investors are increasingly rewarding companies developing targeted therapies capable of interrupting these pathways with greater precision and fewer side effects.Shares of InflaRx N.V. ...
Biotech Surges as Big Money Backs High-Stakes Kidney Disease Push
The immune system has become one of biotech's most important battlegrounds as drug developers race to target inflammatory pathways responsible for some of medicine's most difficult-to-treat diseases. Among the most closely watched areas is the complement system, a network of proteins that can trigger severe tissue damage when overactivated. With growing interest in kidney disorders and autoimmune diseases, investors are increasingly rewarding companies developing targeted therapies capable of interrupting these pathways with greater precision and fewer side effects.Shares of InflaRx N.V. ...
InflaRx N.V. (NASDAQ:IFRX) Short Interest Update
InflaRx N.V. (NASDAQ:IFRX - Get Free Report) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totaling 1,809,027 shares, a decline of 26.2% from the March 31st total of 2,452,174 shares. Approximately 3.0% of the company's stock are short...
InflaRx (IFRX) Expected to Announce Quarterly Earnings on Wednesday
InflaRx (NASDAQ:IFRX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-inflarx-stock...
InflaRx (NASDAQ:IFRX) Coverage Initiated at Oppenheimer
Oppenheimer initiated coverage on InflaRx in a report on Friday. They set an "outperform" rating and a $5.00 price target on the stock...
InflaRx's (IFRX) "Buy" Rating Reaffirmed at Guggenheim
Guggenheim reiterated a "buy" rating and set a $14.00 price target on shares of InflaRx in a report on Tuesday...
InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
InflaRx N.V. (NASDAQ:IFRX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy ratin...
InflaRx (NASDAQ:IFRX) Stock Price Up 32.5% - Should You Buy?
InflaRx (NASDAQ:IFRX) Stock Price Up 32.5% - Still a Buy...
InflaRx N.V. (NASDAQ:IFRX) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of InflaRx N.V. (NASDAQ:IFRX - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven brokerages that are covering the stock, Marketbeat Ratings reports. One...
HC Wainwright Forecasts InflaRx's Q3 Earnings (NASDAQ:IFRX)
InflaRx N.V. (NASDAQ:IFRX - Free Report) - Analysts at HC Wainwright issued their Q3 2026 EPS estimates for InflaRx in a research note issued on Thursday, March 19th. HC Wainwright analyst M. Keller...
<
1
2
...
>
Compact View
Not available
Not available